Alcon introduces Simbrinza for IOP reduction in glaucomaJuly 22, 2013
Alcon, a division of Novartis, announces U.S. Food and Drug Administration approval for Simbrinza™ Suspension, indicated for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. Elevated IOP is the only modifiable risk factor for glaucoma.
Simbrinza is a fixed-dose combination medication that offers a wide range of treatment possibilities due to its strong efficacy and ability to decrease elevated IOP by 21 to 35 percent. In addition, it is the only available, fixed-dose combination therapy for glaucoma in the U.S. without a beta blocker.
“Alcon is the global leader in providing both pharmaceutical and surgical options for patients living with glaucoma,” said Robert Warner, area president, U.S. and Canada for Alcon. “The introduction of Simbrinza further expands our ability to provide effective treatments for patients with elevated IOP. Given its excellent efficacy, established safety profile, and the fact that it is the only available, fixed-dose combination without a beta blocker approved in the U.S., Simbrinza has the potential to reshape the treatment paradigm for glaucoma.”
The new ophthalmic suspension is a fixed-dose combination of a carbonic anhydrase inhibitor (Brinzolamide 1.0%) and an alpha 2 adrenergic receptor agonist (Brimonidine Tartrate 0.2%).
It combines the two drugs into one multi-dose bottle, helping to reduce the medication burden for glaucoma patients. Patients are to administer one drop of Simbrinza into the affected eye(s), three times per day.
“Simbrinza represents an important new option for treating glaucoma patients with elevated IOP,” said Gregory Katz, M.D., Glaucoma Service, St. Joseph Mercy Medical Center, Ann Arbor, Mich. “Glaucoma must be treated over the course of one’s life, and elevated eye pressure must be managed every day. It’s exciting to now have a product available that combines two effective compounds into one multi-dose combination, offering sustained control.”
For more information, visit www.alcon.com.